Literature DB >> 8651752

Glucocorticoid-dependent induction of interleukin-6 receptor expression in human hepatocytes facilitates interleukin-6 stimulation of amino acid transport.

C P Fischer1, B P Bode, K Takahashi, K K Tanabe, W W Souba.   

Abstract

OBJECTIVE: The authors studied the effects of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) on glutamine and alanine transport in isolated human hepatocytes. They also evaluated the role of dexamethasone in modulating this response and its effects on the expression of the plasma membrane high-affinity IL-6 receptor. SUMMARY BACKGROUND DATA: Animal studies indicate that cytokines are important mediators of the increased hepatic amino acid uptake that occurs during cancer and sepsis, but studies in human tissues are lacking. The control of transport by cytokines and cytokine receptor expression in the liver may provide a mechanism by which hepatocytes can modulate amino acid availability during catabolic disease states.
METHODS: Human hepatocytes were isolated from wedge biopsy specimens and plated in 24-well trays. Interleukin-6 and TNF-alpha, in combination with the synthetic glucocorticoid dexamethasone, were added to hepatocytes in culture, and the transport of radiolabeled glutamine and alanine was measured. Fluorescent-activated cell sorter (FACS) analysis was used to study the effects of dexamethasone on IL-6 receptor number in the well-differentiated human hepatoma HepG2.
RESULTS: Both IL-6 and TNF-alpha exerted a small stimulatory effect on alanine and glutamine transport. Dexamethasone alone did not alter transport rates, but pretreatment of cells augmented the effects of both cytokines on carrier-mediated amino acid uptake. Dexamethasone pretreatment and a combination of IL-6 and TNF-alpha resulted in a greater than twofold increase in transport activity. Fluorescent-activated cell sorter analysis demonstrated that dexamethasone induced a threefold increase in the expression of high-affinity IL-6 receptors.
CONCLUSIONS: Interleukin-6 and TNF-alpha work coordinately with glucocorticoids to stimulate amino acid uptake in human hepatocytes. Dexamethasone exerts a permissive effect on cytokine-mediated increases in transport by increasing IL-6 receptor expression on the cell surface. It is likely that this upregulation of IL-6 receptors "primes" human liver cells for subsequent stimulation by cytokines. The resulting increase in hepatic amino acid transport provides the liver with substrate to support key metabolic pathways during catabolic states.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8651752      PMCID: PMC1235193          DOI: 10.1097/00000658-199605000-00017

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  25 in total

Review 1.  Stimulation of hepatic acute phase response by cytokines and glucocorticoids.

Authors:  H Baumann; K R Prowse; S Marinković; K A Won; G P Jahreis
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

2.  Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells.

Authors:  H Schooltink; H Schmitz-Van de Leur; P C Heinrich; S Rose-John
Journal:  FEBS Lett       Date:  1992-02-10       Impact factor: 4.124

3.  Interleukin-6 and dexamethasone work coordinately to augment hepatic amino acid transport.

Authors:  K T Watkins; P S Dudrick; E M Copeland; W W Souba
Journal:  J Trauma       Date:  1994-04

4.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

5.  Glutamine: a major gluconeogenic precursor and vehicle for interorgan carbon transport in man.

Authors:  N Nurjhan; A Bucci; G Perriello; M Stumvoll; G Dailey; D M Bier; I Toft; T G Jenssen; J E Gerich
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

Review 6.  Cytokine control of nutrition and metabolism in critical illness.

Authors:  W W Souba
Journal:  Curr Probl Surg       Date:  1994-07       Impact factor: 1.909

7.  Ciliary neurotrophic factor regulates fibrinogen gene expression in hepatocytes by binding to the interleukin-6 receptor.

Authors:  J E Nesbitt; N L Fuentes; G M Fuller
Journal:  Biochem Biophys Res Commun       Date:  1993-01-29       Impact factor: 3.575

8.  TNF-stimulated arginine transport by human vascular endothelium requires activation of protein kinase C.

Authors:  M Pan; M Wasa; D S Lind; J Gertler; W Abbott; W W Souba
Journal:  Ann Surg       Date:  1995-05       Impact factor: 12.969

9.  Survival from sepsis. The significance of altered protein metabolism regulated by proteolysis inducing factor, the circulating cleavage product of interleukin-1.

Authors:  G H Clowes; E Hirsch; B C George; L M Bigatello; J E Mazuski; C A Villee
Journal:  Ann Surg       Date:  1985-10       Impact factor: 12.969

10.  Enhanced hepatic amino acid transport in tumor-bearing rats is partially blocked by antibody to tumor necrosis factor.

Authors:  Y Inoue; B P Bode; E M Copeland; W W Souba
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

View more
  3 in total

1.  Fibrinogen-like protein 1, a hepatocyte derived protein is an acute phase reactant.

Authors:  Zhilin Liu; Chinweike Ukomadu
Journal:  Biochem Biophys Res Commun       Date:  2007-11-26       Impact factor: 3.575

2.  The impact of endogenous annexin A1 on glucocorticoid control of inflammatory arthritis.

Authors:  Hetal B Patel; Kristin N Kornerup; Andre' L F Sampaio; Fulvio D'Acquisto; Michael P Seed; Ana Paula Girol; Mohini Gray; Costantino Pitzalis; Sonia M Oliani; Mauro Perretti
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

Review 3.  Strategies for enrichment and selection of stem cell-derived tissue precursors.

Authors:  Harold S Bernstein; William C Hyun
Journal:  Stem Cell Res Ther       Date:  2012-05-10       Impact factor: 6.832

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.